Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need.
At Booth #7049, Kiniksa will be highlighting efforts related to recurrent pericarditis, a rare autoinflammatory condition with no FDA-approved therapies. Current treatments, utilizing nonspecific inhibitors of inflammation, can result in significant morbidity with chronic use.
Kiniksa is evaluating the efficacy and safety of rilonacept in participants with recurrent pericarditis in a trial called RHAPSODY (ClinicalTrials.gov Identifier: NCT03737110).
Rilonacept in recurrent pericarditis is an investigational drug.